Table 3.
Range of estimated (simulated) hepatocyte loss as a function of observed plasma peak alanine transaminase (ALT) range in phase I cimaglermin alfa‐treated subjects with 100% apoptosis or 100% necrosis as the cell death modality
Peak ALT range (U/L) |
Hepatocyte loss (%) estimated with 100% apoptosis (lower bound – upper bound) |
Hepatocyte loss (%) estimated with 100% necrosis (lower bound – upper bound) |
---|---|---|
1–100 | 0.0–7.0 | 0.0–2.8 |
101–200 | 4.9–9.9 | 2.7–6.2 |
201–300 | 6.6–12.4 | 2.7–7.8 |